{"disease":{"id":"human-immunodeficiency-virus-hiv-infections","name":"human immunodeficiency virus hiv infections"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04772469","title":"Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men","phase":"NA","overall_status":"COMPLETED","enrollment_count":934,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT01231516","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":724,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02831764","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02831673","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":719,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02951052","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":618,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03310515","title":"Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men","phase":"","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT01910402","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02120352","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":309,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01448707","title":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"Janssen-Cilag International NV","has_results":true},{"nct_id":"NCT01641809","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01536873","title":"Dolutegravir Expanded Access Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02741557","title":"Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02178592","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01803074","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03729778","title":"Impact of HIV-1 and Aging on Mucosal Vaccine Responses","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Eastern Colorado Health Care System","has_results":false},{"nct_id":"NCT03231943","title":"GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT00071760","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03314064","title":"Phase 4 Study of Dolutegravir (DTG) in Russian Federation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03368053","title":"Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03045861","title":"Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03234036","title":"A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01031472","title":"A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02478463","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01068925","title":"Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT01231529","title":"GSK1349572 Hepatic Impairment Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02354937","title":"Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03149848","title":"Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01195974","title":"A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02075593","title":"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05130086","title":"A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}